Genentech : Tecentriq Combination Reduces Risk Of Cancer Returning In People With Liver Cancer
17/4 04:42
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) plus Avastin (bevacizumab) demonstrated a statistically significant improvement in recurrence-free survival (RFS) in people with h...